

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the annual results announcement for the year ended December 31, 2024 of Transcenta Holding Limited (the “**Company**”) dated March 30, 2025 (the “**Announcement**”). Unless otherwise stated, capitalized terms used herein shall bear the same meanings as defined in the Announcement.

The Company wishes to clarify that the first two paragraphs on page 49 of the Announcement under the heading “Impairment assessment of goodwill, property, plant and equipment, intangible assets not yet ready for use and right-of-use assets” should be removed in its entirety (including the heading) (the “**Amended Announcement**”). The Auditor reconfirmed that the extract of its disclaimer of opinion as set out in the Announcement and Amended Announcement related to the going concern issue only (and not any other issues). The Board and the Auditor believe that the Amended Announcement is unequivocal and avoids any unnecessary confusion or misunderstanding. The Company and the Auditor confirm that the Amended Announcement is in full compliance with Rule 13.50A of the Listing Rules.

Save as disclosed in this announcement, all information set out in the Announcement remains unchanged.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
*Executive Director, Chairman
and Chief Executive Officer*

Hong Kong, March 31, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.